

BREATHTEC BIOMEDICAL INC.

Suite 890, 789 West Pender Street
Vancouver, British Columbia, Canada V6C 1H2

Breathtec Biomedical Announces Signing of License Agreement with University of Florida Research Foundation; Enters into IR Agreement and Appoints Director

VANCOUVER, BRITISH COLUMBIA – August 30, 2016 – Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (XFRA: BTI) (OTCQB: BTHCF) (the “**Company**” or “**Breathtec**”), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases is pleased to announce the signing of a license agreement dated as of June 18, 2016 (the “**License Agreement**”) between the Company and the University of Florida Research Foundation, a nonprofit Florida corporation (“**UFRF**”) with respect to an exclusive royalty-bearing license to certain UFRF patent rights and a non-exclusive royalty bearing license to certain UFRF know-how to enable commercial advancements in the field of infections detection (the “**License**”).

Pursuant to the terms of the License Agreement, the Company has been granted the License for a period of ten years after the first commercial sale of a licensed product (with an option to extend for additional five year terms). As consideration for the License, and subject to regulatory approval, the Company will pay UFRF a license issue fee and issue 468,162 common shares of the Company (“**Shares**”). In addition, the Company will pay an annual license maintenance fee and will make payments upon meeting certain development, regulatory and commercialization milestones. Upon commencement of commercial production, the Company will pay a royalty on all net sales.

All Shares issued to UFRF will be subject to a 4 month hold period pursuant to applicable securities laws.

The Company is also pleased to announce that it has engaged Equities Media Inc. (“**Equities**”) to provide investor relations services for a term of six months. In consideration for providing the services, the Company will pay a cash fee of \$25,000 and will issue 60,000 shares at a deemed price of \$0.25 per share. Equities does not have any direct or indirect interest in the Company.

In addition, the Company is pleased to announce the appointment of Guy LaTorre to the Company’s board of directors (for more details concerning Mr LaTorre, please see the Company’s press release of June 20, 2016). Concurrent with his appointment, and subject to regulatory approval, an aggregate of 250,000 options to acquire common shares in the capital of the Company will be granted to Mr. LaTorre, each such option being exercisable into one common share at a price of \$0.25 per share for a period of 60 months.

The Company announces the resignation of Michael Costanzo as a director of the Company effective immediately. The Company wishes to thank Mr. Costanzo for his contributions to the board of directors over the past year. Mr. Costanzo will remain with the Company in the role of Chief Technology Officer.

For more information, please visit: www.breathtecbiomedical.com.

ON BEHALF OF THE BOARD

"Kal Malhi"
President & Director

For further information, please contact:
CORE Capital Partners
Telephone: 604-566-9233

Email: investors@ccpartnersinc.com

Website: www.breathtecbiomedical.com

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.